Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340737 · ClinicalTrials.gov registry record · Phase 1
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
A Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT06340737: Recruiting Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Stanford University.
NCT06340737 is a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 148 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (44% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06340737, a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.
Primary Outcome
Rate of successful manufacture of CD22CART cells at the target dose level that meet required release specifications in Cohort 1, Cohort 2, and Cohort 3.
Conditions Studied
Interventions
- DRUG CD22CART Infusion
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2031-04 |
| Phase | Phase 1 |
What NCT06340737 shows while recruiting
NCT06340737 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (44% higher).
The record links to 8 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD22CART Infusion is the first listed.
NCT06340737 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06340737 about?
NCT06340737 is a clinical study titled "AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas". This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and d...
What is the current status of trial NCT06340737?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2024-03-29. Estimated completion is 2031-04.
What conditions does trial NCT06340737 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Large B-cell Lymphoma.
What interventions are being tested in trial NCT06340737?
The interventions under investigation include: CD22CART Infusion (DRUG).
Who is sponsoring clinical trial NCT06340737?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340737 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06340737's enrollment target sits among peer trials
148 21st of 102 higher than 82 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
SynKIR-310 for Relapsed/Refractory B-NHL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI